OD
ODTX
Odyssey Therapeutics, Inc.
$17.12
+4.20%
$770.3M
No data for this timeframe.
Vol
Market Cap$770.3M
Cap SizeSmall Cap
Insider Activity7B / 1S
Insider Net $$69.3M
SEC Reports14
Press Releases1
Recent Activity
May 13, 2026
SEC
Odyssey Therapeutics insiders and a major investor (TPG GP A, LLC) have made significant open-market purchases totaling
CLUSTER — Impact 7/10
May 12, 2026
SEC
Odyssey Therapeutics insiders, including Director Li Nan and Director Chu Shelley, made open-market purchases totaling ~
CLUSTER — Impact 7/10
May 12, 2026
SEC
Insider cluster at Odyssey Therapeutics shows $20.2M in open-market purchases by directors Li Nan and Chu Shelley at $18
CLUSTER — Impact 7/10
May 12, 2026
short_interest
FTD: ODTX — 61,094 shares ($1.1M) failed to deliver
Settlement: 20260512, Price: $17.45, FTD Value: $1,066,090.3, ODYSSEY THERAPEUTICS INC COM
May 11, 2026
Insider
Opipari Anthony W. sold 6,965 shares
See Remarks @ $0.00 ($0.00)
May 11, 2026
Insider
Opipari Anthony W. sold 541 shares
See Remarks @ $0.00 ($0.00)
May 11, 2026
Insider
Opipari Anthony W. sold 4 shares
See Remarks @ $18.00 ($72.00)
May 8, 2026
Press
Odyssey Therapeutics priced its upsized IPO of 15.5M shares at $18.00/share, with a concurrent private placement of 1.39
Impact 5/10
Price Targets
$32.00
+87.2% upside
Strong Buy
Current $17.09
Low $26.00
Median $30.00
High $40.00
3 analysts
$26.00
$40.00
Analyst Ratings
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 2, 2026 | Cantor Fitzgerald | INITIATE | Overweight |
| Jun 2, 2026 | TD Cowen | INITIATE | Buy |
| Jun 2, 2026 | Wedbush | INITIATE | Outperform |
| Jun 2, 2026 | JP Morgan | INITIATE | Overweight |
| Jun 2, 2026 | Oppenheimer | INITIATE | Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.28 | $-1.43 — $-1.13 | 2 | |
| Next Q | $-0.83 | $-0.90 — $-0.74 | 3 | |
| Current FY | $-3.56 | $-3.89 — $-3.23 | 2 | |
| Next FY | $-3.83 | $-4.70 — $-2.90 | -7% YoY | 3 |
Latest Reports
BULLISH
CLUSTER
7/10
Odyssey Therapeutics insiders and a major investor (TPG GP A, LLC) have made significant open-market purchases totaling
May 13, 2026
BULLISH
CLUSTER
7/10
Odyssey Therapeutics insiders, including Director Li Nan and Director Chu Shelley, made open-market purchases totaling ~
May 12, 2026
NEUTRAL
Press
5/10
Odyssey Therapeutics priced its upsized IPO of 15.5M shares at $18.00/share, with a concurrent private placement of 1.39
May 8, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 11, 2026 | Opipari Anthony | C | $0.00 |
| May 11, 2026 | Opipari Anthony | M | $0.00 |
| May 11, 2026 | Opipari Anthony | F | $72.00 |
| May 11, 2026 | Opipari Anthony | C | $0.00 |
| May 11, 2026 | Opipari Anthony | C | $0.00 |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
15 unique insiders with 8 transactions. Net insider value: $69.3M ($69.3M bought, $19.2K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 11, 2026 | Opipari Anthony W. | See Remarks | C | 6,965 | $0.00 | $0.00 |
| May 11, 2026 | Opipari Anthony W. | See Remarks | M | 541 | $0.00 | $0.00 |
| May 11, 2026 | Opipari Anthony W. | See Remarks | F | 4 | $18.00 | $72.00 |
| May 11, 2026 | Opipari Anthony W. | See Remarks | C | 18,531 | $0.00 | $0.00 |
| May 11, 2026 | Opipari Anthony W. | See Remarks | C | 11,083 | $0.00 | $0.00 |
| May 11, 2026 | Opipari Anthony W. | See Remarks | C | 20,000 | $0.00 | $0.00 |
| May 11, 2026 | Opipari Anthony W. | See Remarks | C | 17,545 | $0.00 | $0.00 |
| May 11, 2026 | Chu Shelley | Director | BUY | 11,111 | $18.00 | $200.0K |
| May 11, 2026 | Opipari Anthony W. | See Remarks | M | 5,263 | $0.00 | $0.00 |
| May 11, 2026 | Glick Gary D | See Remarks | C | 27,386 | $0.00 | $0.00 |
| May 11, 2026 | Glick Gary D | See Remarks | C | 166,116 | $0.00 | $0.00 |
| May 11, 2026 | Glick Gary D | See Remarks | C | 100,000 | $0.00 | $0.00 |
| May 11, 2026 | Li Nan (LN) | Director | C | 1,709,543 | $0.00 | $0.00 |
| May 11, 2026 | Li Nan (LN) | Director | BUY | 1,111,111 | $18.00 | $20.0M |
| May 11, 2026 | Li Nan (LN) | Director | C | 16,611,626 | $0.00 | $0.00 |
| May 11, 2026 | LEIDEN JEFFREY M | Director | C | 28,698 | $0.00 | $0.00 |
| May 11, 2026 | LEIDEN JEFFREY M | Director | M | 2,963 | $0.00 | $0.00 |
| May 11, 2026 | LEIDEN JEFFREY M | Director | F | 17 | $18.00 | $306.00 |
| May 11, 2026 | LEIDEN JEFFREY M | Director | C | 79,166 | $0.00 | $0.00 |
| May 11, 2026 | LEIDEN JEFFREY M | Director | C | 100,000 | $0.00 | $0.00 |
| May 11, 2026 | LEIDEN JEFFREY M | Director | C | 96,002 | $0.00 | $0.00 |
| May 11, 2026 | LEIDEN JEFFREY M | Director | M | 28,800 | $0.00 | $0.00 |
| May 11, 2026 | SR ONE CAPITAL MANAGEMENT, LLC | 10%+ Owner | C | 474,048 | $0.00 | $0.00 |
| May 11, 2026 | SR ONE CAPITAL MANAGEMENT, LLC | 10%+ Owner | X | 191,541 | $0.00 | $0.00 |
| May 11, 2026 | SR ONE CAPITAL MANAGEMENT, LLC | 10%+ Owner | SELL | 1,065 | $18.00 | $19.2K |
| May 11, 2026 | SR ONE CAPITAL MANAGEMENT, LLC | 10%+ Owner | X | 1,861,211 | $0.00 | $0.00 |
| May 11, 2026 | SR ONE CAPITAL MANAGEMENT, LLC | 10%+ Owner | BUY | 222,222 | $18.00 | $4.0M |
| May 11, 2026 | SR ONE CAPITAL MANAGEMENT, LLC | 10%+ Owner | C | 4,606,320 | $0.00 | $0.00 |
| May 11, 2026 | SR ONE CAPITAL MANAGEMENT, LLC | 10%+ Owner | C | 1,299,842 | $0.00 | $0.00 |
| May 11, 2026 | SR ONE CAPITAL MANAGEMENT, LLC | 10%+ Owner | C | 544,162 | $0.00 | $0.00 |
| May 11, 2026 | SR ONE CAPITAL MANAGEMENT, LLC | 10%+ Owner | C | 600,142 | $0.00 | $0.00 |
| May 11, 2026 | SR ONE CAPITAL MANAGEMENT, LLC | 10%+ Owner | C | 6,644,650 | $0.00 | $0.00 |
| May 11, 2026 | TPG GP A, LLC | J | 423,111 | $0.00 | $0.00 | |
| May 11, 2026 | TPG GP A, LLC | C | 1,880,497 | $0.00 | $0.00 | |
| May 11, 2026 | TPG GP A, LLC | BUY | 1,388,889 | $18.00 | $25.0M | |
| May 11, 2026 | TPG GP A, LLC | J | 423,111 | $0.00 | $0.00 | |
| May 11, 2026 | TPG GP A, LLC | C | 18,272,789 | $0.00 | $0.00 | |
| May 8, 2026 | Haas Jason | Chief Financial Officer | BUY | 1,000 | $20.00 | $20.0K |
| May 8, 2026 | LEIDEN JEFFREY M | Director | BUY | 5,000 | $20.00 | $100.0K |
| May 8, 2026 | Dimension Capital II, L.P. | Director | C | 1,709,543 | $0.00 | $0.00 |
| May 8, 2026 | Dimension Capital II, L.P. | Director | BUY | 1,111,111 | $18.00 | $20.0M |
| May 8, 2026 | Dimension Capital II, L.P. | Director | C | 16,611,626 | $0.00 | $0.00 |
| May 7, 2026 | Tatsis Ourania | Director | A | 27,393 | $0.00 | $0.00 |
| May 7, 2026 | Walbert Timothy P | Director | A | 27,393 | $0.00 | $0.00 |
| May 7, 2026 | SMITH IAN F | Director | A | 27,393 | $0.00 | $0.00 |
| May 7, 2026 | Odegard Valerie | Director | A | 27,393 | $0.00 | $0.00 |
| May 7, 2026 | Opipari Anthony W. | See Remarks | A | 250,203 | $0.00 | $0.00 |
| May 7, 2026 | Glick Gary D | See Remarks | A | 884,450 | $0.00 | $0.00 |
| May 7, 2026 | Todd Collin M | See Remarks | A | 93,904 | $0.00 | $0.00 |
| May 7, 2026 | Dales Natalie | See Remarks | A | 79,773 | $0.00 | $0.00 |
14 SEC filing reports analyzed. Sentiment: 3 bullish, 0 bearish, 3 mixed, 8 neutral. Avg impact: 3.9/10.
BULLISH
CLUSTER
7/10
Odyssey Therapeutics insiders and a major investor (TPG GP A, LLC) have made significant open-market
May 13, 2026
BULLISH
CLUSTER
7/10
Odyssey Therapeutics insiders, including Director Li Nan and Director Chu Shelley, made open-market
May 12, 2026
BULLISH
CLUSTER
7/10
Insider cluster at Odyssey Therapeutics shows $20.2M in open-market purchases by directors Li Nan an
May 12, 2026
MIXED
424B4
6/10
Odyssey Therapeutics priced its IPO at $18.00 per share, raising $279.0 million (15.5M shares) plus
May 8, 2026
MIXED
EFFECT
6/10
Odyssey Therapeutics' IPO registration (S-1) became effective on May 7, 2026, clearing the final reg
May 8, 2026
NEUTRAL
3
2/10
Timothy P. Walbert filed a Form 3 initial statement of beneficial ownership with the SEC upon becomi
May 8, 2026
NEUTRAL
3
2/10
Odyssey Therapeutics filed two Form 3 initial beneficial ownership statements for new insiders Ouran
May 8, 2026
NEUTRAL
3
2/10
Jolie M. Siegel filed a Form 3 initial beneficial ownership report upon becoming Executive Vice Pres
May 8, 2026
NEUTRAL
3
2/10
Jeffrey M. Leiden filed a Form 3 initial statement of beneficial ownership with the SEC, reporting d
May 8, 2026
NEUTRAL
3
2/10
Simeon George and SR One Capital Management, LLC filed a Form 3 initial statement of beneficial owne
May 8, 2026
NEUTRAL
3
2/10
Ian F. Smith filed a Form 3 initial statement of beneficial ownership with the SEC, reporting direct
May 8, 2026
NEUTRAL
3
1/10
Carolyn Ng filed an initial statement of beneficial ownership (Form 3) with the SEC, reporting no se
May 8, 2026
NEUTRAL
3
2/10
Paulina Hill filed a Form 3 initial statement of beneficial ownership with the SEC for Odyssey Thera
May 8, 2026
MIXED
S-1/A
6/10
Odyssey Therapeutics, a clinical-stage biopharma focused on autoimmune/inflammatory diseases, filed
May 4, 2026
Analyst Price Targets
$32.00 mean target
+87.2% upside
Strong Buy (1.20)
$26.00 Low
$40.00 High
| Metric | Value |
|---|---|
| Current Price | $17.09 |
| Target Low | $26.00 |
| Target Mean | $32.00 |
| Target Median | $30.00 |
| Target High | $40.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (1.20) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$-1.28 | $-1.43 | $-1.13 | — | — | — | $0.0B | — | 2 |
| Next Q 2026-06-30 |
$-0.83 | $-0.90 | $-0.74 | — | — | — | $0.0B | — | 3 |
| Current FY 2026-12-31 |
$-3.56 | $-3.89 | $-3.23 | — | — | — | $0.0B | — | 2 |
| Next FY 2027-12-31 |
$-3.83 | $-4.70 | $-2.90 | -7.4% | — | — | $0.0B | 0.0% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.280 | |
| 7d ago | $0.000 | -1.280 |
| 30d ago | $0.000 | -1.280 |
| 60d ago | $0.000 | -1.280 |
| 90d ago | $0.000 | -1.280 |
5 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 5 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 2, 2026 | Cantor Fitzgerald | INITIATE | — | Overweight |
| Jun 2, 2026 | TD Cowen | INITIATE | — | Buy |
| Jun 2, 2026 | Wedbush | INITIATE | — | Outperform |
| Jun 2, 2026 | JP Morgan | INITIATE | — | Overweight |
| Jun 2, 2026 | Oppenheimer | INITIATE | — | Outperform |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 12, 2026
short_interest
FTD: ODTX — 61,094 shares ($1.1M) failed to deliver
Settlement: 20260512, Price: $17.45, FTD Value: $1,066,090.3, ODYSSEY THERAPEUTICS INC COM
May 11, 2026
short_interest
FTD: ODTX — 172,406 shares ($2.8M) failed to deliver
Settlement: 20260511, Price: $16.42, FTD Value: $2,830,906.52, ODYSSEY THERAPEUTICS INC COM
May 8, 2026
offering
Odyssey Therapeutics Announces Pricing of Upsized Initial Public Offering
Odyssey Therapeutics, Inc. announces pricing of its upsized IPO of 15,500,000 shares of its common stock at an IPO price of $18 per share.